SESSION 8: ASSESSING PEDIATRIC RESEARCH: CONSIDERING INDIVIDUAL RISK AND SOCIETAL BENEFIT
DR. WAGNER: Okay. If we can have the Commissioners take their seats?
And we will begin our Session 8, after a very productive Session 7. Thank you, Amy. That was excellent.
And so, at this point in our meeting, we do switch gears. We have been talking about genomics and whole genomic sequencing. We are going to shift to medical countermeasures.